Dublin, Jan. 08, 2026 (GLOBE NEWSWIRE) — The “Bioprocessing Global Market Opportunities and Strategies to 2034” has been added to ResearchAndMarkets.com’s offering.
The global bioprocessing market, evaluated from 2019 to 2024 and forecasted through 2029 to 2034, is experiencing significant growth. By 2024, the market reached approximately $62.34 billion, showing a CAGR of 12.93% from 2019. The projection for 2029 is $122.67 billion, growing at 14.50%, and estimated to hit $230.55 billion by 2034 with a CAGR of 13.45% from 2029.
The industry’s development has been propelled by government biotechnology support, expansion of pharmaceutical sectors, biotech R&D investment, and a rise in personalized medicine demand. Conversely, challenges such as high manufacturing energy and water consumption, and skilled labor shortages posed a drag on historic growth.
The future of the bioprocessing market looks promising, driven by the expansion of CDMOs, a surge in rare disease and orphan drug development, the increasing demand for cell and gene therapies, and the rising prevalence of chronic diseases. However, potential obstacles such as trade wars, long development timelines, and contamination risks might impede growth.
Currently, North America leads the bioprocessing market, contributing 43.40% or $27.05 billion in 2024, followed by regions like Asia Pacific and Western Europe. The fastest-growing markets are anticipated to be in Asia Pacific and the Middle East, with CAGRs of 16.22% and 15.63%, respectively. The industry remains fragmented, with top players making up 23.04% of the market in 2024. Leading the pack is Sartorius AG (Novasep) with 4.67%, followed by Thermo Fisher Scientific Inc and others.
The market segments by type into upstream and downstream processing, with downstream processing representing the largest segment, projected to grow at a CAGR of 14.87% from 2024 to 2029. In terms of application, monoclonal antibodies dominate, while cell and gene therapy is the fastest-growing segment. Regarding end users, biopharmaceutical companies hold the largest share, yet contract manufacturing organizations will see rapid growth. The commercial-scale operation is the most substantial segment and is expected to maintain its pace as the fastest-growing from 2024 to 2029.
In the product segmentation, consumables account for the largest share and will experience robust growth. Emerging opportunities lie in downstream processing, cell and gene therapy, biopharmaceutical companies, commercial-scale operations, and consumables, with notable growth expected in the USA.
Key market strategies include focusing on merging spectral cytometry with real-time imaging, expanding automated cell and gene therapy manufacturing, refining TFF consumables, shifting toward animal-free testing, advancing high-parameter spectral flow cytometry, and introducing next-gen cell line development systems. Market players are expanding capabilities through partnerships, new facilities, and product launches.
For enhanced market positioning, companies should adopt integrated spectral cytometry, expand therapeutics in emerging markets, advance TFF consumables, encourage animal-free testing, focus on downstream processing, penetrate emerging markets, and continue efforts in developed markets. Embracing innovations in cell and gene therapies and leveraging contract manufacturing will further tap into growth avenues.
Key Coverage Includes:
- Introduction and Market Characteristics: Insight into market segmentations and analytical frameworks.
- Key Trends: Current and prospective trends influencing the global market.
- Growth Analysis and Strategic Framework: Detailed PESTEL analysis and market growth forecasts.
- Global Market Size and Growth: Historical and forecast values, drivers, and controls of market growth.
- Regional and Country Analysis: Comparative analysis of regional market values and shares.
- Market Segmentation: Comprehensive segmentation by type, application, end user, scale, and product.
- Competitive Landscape: Market shares and profiles of leading companies.
- Key Mergers and Acquisitions: Financial highlights of significant market-shaping deals.
- Opportunities and Strategies: Growth opportunities across segments and geographic strategies.
- Conclusions and Recommendations: Strategic recommendations for bioprocessing market stakeholders.
Markets Covered:
- Type: Upstream and Downstream Processing
- Application: Monoclonal Antibodies, Cell and Gene Therapy, Vaccines, etc.
- End User: Biopharmaceutical Companies, Academic Research Institutes, etc.
- Scale: Commercial, Preclinical, Clinical
- Product: Equipment, Consumables, Services
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 434 |
| Forecast Period | 2024 – 2034 |
| Estimated Market Value (USD) in 2024 | $62.34 Billion |
| Forecasted Market Value (USD) by 2034 | $230.55 Billion |
| Compound Annual Growth Rate | 14.0% |
| Regions Covered | Global |
Companies Featured
- Sartorius AG (Novasep)
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Merck KGaA (MilliporeSigma)
- Lonza Group AG
- Agilent Technologies Inc.
- Cytiva AB
- Bristol Myers Squibb Company
- GE Healthcare Technologies, Inc.
- Pfizer Inc.
- WuXi Biologics
- GE Healthcare Life Sciences (Now part of Cytiva)
- Sartorius (China)
- Asahi Kasei Medical
- Duoning Biotech
- Merck KGaA
- Cytiva (South Korea)
- Bioneer Corporation
- Scaffold Biosciences Pvt. Ltd.
- Thermo Fisher Scientific
- Samsung Biologics
- Daeil Systech Co., Ltd.
- Laboratorios Farmaceuticos Rovi
- Cellerix
- BSP Pharmaceuticals
- Stevanato Group
- Repligen
- Fujifilm Diosynth Biotechnologies
- Saint-Gobain Life Sciences
- Sartorius
- Sartorius Croatia
- Polpharma Biologics
- Wacker Chemie AG
- Enzym Group
- Ayoxxa Biosystems
- DuPont
- Danaher Corporation
- Sartorius AG
- Ecolab Life Sciences
- Takara Bio Inc
- Cytiva
- OmniaBio
- Ichor Life Sciences Inc
- Sigma-Aldrich
- TECNIC Bioprocess Solutions
- Novozymes A/S
- mAbxience
- Repligenclxiv
- Sartoriusclxv
- Stamm Biotech
- GCC Biotech
- BioGen
- BIOKIM
- Lonza
- Afrigen Biologics and Vaccines
- EVA Pharma
- Dei BioPharma Ltd
For more information about this report visit https://www.researchandmarkets.com/r/vswiwe
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
